Skip to main content

COVID Meds Like Paxlovid Will Soon Have Big Price Tags

Medically reviewed by Drugs.com.

By Cara Murez HealthDay Reporter

MONDAY, Oct. 30, 2023 -- Americans have been getting COVID treatments such as Paxlovid for free, but that’s about to end.

The medications will enter the private market this week, the Associated Press reported.

The price for a five-day course of Paxlovid, made by Pfizer, will be $1,390.

Merck has not confirmed a price for its COVID treatment, Lagevrio, but told the AP that it will offer the treatment free to patients “who, without assistance, could not otherwise afford the product.”

The pills will still be available at no cost until those bought earlier by the federal government run out at pharmacies, hospitals and doctor’s offices, according to U.S. Health and Human Services officials. The government paid Pfizer $5 billion for 10 million courses of Paxlovid in 2021.

Once those are gone, those with private insurance may notice a co-pay charge, the AP reported.

People on Medicaid, Medicare or without medical insurance will not pay any out-of-pocket costs for these treatments through 2024, and Pfizer will offer co-pay assistance for Paxlovid through 2028.

The Department of Veterans Affairs, the Department of Defense and Indian Health Service will still have access to government stores of Paxlovid, the AP reported.

The federal government will also keep 1 million treatment courses in its stockpile.

“Pfizer is committed to a smooth commercial transition and is working collaboratively with the U.S. government and health care stakeholders to ensure broad and equitable access to this important medicine for all eligible patients,” the company told the AP.

Medical suppliers can begin ordering the treatment from the drug companies starting this week.

The U.S. Food and Drug Administration granted full approval to Paxlovid earlier this year. It’s meant for adults with COVID who have a high risk of hospitalization or death, including older adults and those with chronic conditions such as obesity, diabetes or asthma.

Sources

  • Associated Press

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted October 2023

Further Support and Information on COVID-19

Read this next

Extended Course of Paxlovid Adds No Benefit for Those With Long COVID

FRIDAY, June 7, 2024 -- An extended course of the antiviral drug Paxlovid won’t ease a person’s Long COVID symptoms, a new study finds. People who took Paxlovid for...

FDA Panel OKs New COVID Vaccine for Fall

THURSDAY, June 6, 2024 -- A U.S. Food and Drug Administration advisory panel on Wednesday recommended updating the formula for COVID vaccines ahead of a fall campaign that will...

Long COVID's Toll Outlined in New Report

THURSDAY, June 6, 2024 -- Long COVID continues to plague millions of Americans as the health costs of the pandemic linger four years later, a new report warns. In a hefty...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.